O
PDLI

OppenheimerFunds’s PDL BioPharma, Inc. PDLI Stock Holding History

OppenheimerFunds’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-12,226
Closed -$36K – 1858
2018
Q1 		$36K Buy
+12,226
New +$33.4K ﹤0.01% 1771

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

OppenheimerFunds's PDLI Position: Q2 2018 in Review

OppenheimerFunds sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 12,226 shares — an estimated $36K sold.

OppenheimerFunds first reported a position in PDLI in Q1 2018 and held it in 1 quarter. The position peaked at $36K in Q1 2018. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

  • OppenheimerFunds reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
  • OppenheimerFunds sold 12,226 PDL BioPharma, Inc. shares in Q2 2018, an estimated $36K.
  • OppenheimerFunds first reported a position in PDL BioPharma, Inc. in Q1 2018 and held it in 1 quarter.
  • OppenheimerFunds's PDL BioPharma, Inc. position peaked at $36K in Q1 2018.
  • 163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on OppenheimerFunds's 13F filing for Q2 2018, filed 13 Aug 2018.